Table 3.
Factor | Renal remission at end of follow-up
|
P | |
---|---|---|---|
+
|
-
|
||
(n = 12) | (n = 8) | ||
Median age, years (range) | 24.5 (18 to 35) | 24 (17 to 37) | NS |
Black ethnicity, n (%) | 1 (8) | 6 (75) | 0.004 |
Class III/IV LN, n (%) | 10 (83) | 5 (62) | NS |
RPGN, n (%) | 0 | 3 (37) | 0,05 |
Median Pu, g/day (range) | 5.5 (0.5 to 25) | 4.5 (3 to 9) | NS |
Median serum Alb, g/L (range) | 24.5 (19 to 40) | 19.5 (11 to 28) | 0.08 |
Median eGFR, ml/min/1.73 m2 (range) | 72 (9 to 150) | 62 (0 to 133) | NS |
Median C3, % normal (range) | 44 (15 to 121) | 39 (30 to 130) | NS |
Baseline positive anti-dsDNA Ab, n (%) | 11 (92) | 6/7 (86) | NS |
Negative anti-dsDNA Ab at end of follow-up (among positive at baseline), n (%) | 5 (45%) | 2 (33%) | NS |
IV Cs, n (%) | 8 (75%) | 4 (50%) | NS |
CYP, n (%) | 1 (8%) | 2 (25%) | NS |
MMF, n (%) | 1 (8%) | 2 (25%) | NS |
B cell depletion at M1 | 11/11 | 1/6 | <0.001 |
Overall B cell depletion | 11/11 | 3/6 | 0.03 |
P values are by Fisher's exact test for categorical data and by Wilcoxon rank sum test with continuity correction for continuous data. NS, not significant; LN, lupus nephritis; RPGN, rapidly progressive glomerulonephritis; Pu, baseline proteinuria; serum Alb, baseline albuminemia; eGFR, baseline estimated glomerular filtration rate; C3: baseline C3 complement; anti-dsDNA Ab, anti-double stranded DNA antibody; IV Cs, intravenous corticosteroids associated with rituximab; CYP, cyclophosphamide associated with rituximab; MMF, mycophenolate mofetil associated wit RTX; M1, 1 mo after rituximab initiation.